Empowered Funds LLC Invests $180,000 in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Empowered Funds LLC acquired a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,923 shares of the life sciences company’s stock, valued at approximately $180,000.

Other large investors have also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in shares of Integra LifeSciences by 18.7% in the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock valued at $7,294,000 after purchasing an additional 63,266 shares during the period. Versor Investments LP acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at $612,000. BNP Paribas Financial Markets lifted its stake in shares of Integra LifeSciences by 824.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock valued at $2,031,000 after purchasing an additional 99,685 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at $960,000. Finally, State of Alaska Department of Revenue lifted its stake in shares of Integra LifeSciences by 144.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company’s stock valued at $2,393,000 after purchasing an additional 77,825 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.10% of the stock is owned by company insiders.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $21.13 on Friday. The firm’s fifty day moving average price is $23.71 and its two-hundred day moving average price is $21.81. The stock has a market cap of $1.63 billion, a PE ratio of -234.75, a PEG ratio of 0.73 and a beta of 1.17. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $45.11. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Analysts Set New Price Targets

IART has been the topic of a number of analyst reports. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Morgan Stanley began coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.